Position in ILMN
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$985,527
+$122,495 QoQ
Shares Held
5,605
-14.8% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#445
of 932 holders
Holding Since
Mar 2021
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ILMN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026FOX RUN MANAGEMENT, L.L.C. holds $15,330,453 across 13 Diagnostics & Research names. ILMN ranks #7 (6.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IDXX |
Idexx Laboratories Inc /De
|
4,967 | $2,614,827 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
4,373 | $2,192,447 | |
| 3 | GH |
Guardant Health, Inc.
|
14,194 | $2,129,525 | |
| 4 | NTRA |
Natera, Inc.
|
5,952 | $1,615,670 | |
| 5 | ICLR |
Icon PLC
|
8,750 | $1,519,962 | |
| 6 | DHR |
Danaher Corp /De/
|
7,453 | $1,419,647 | |
| 7 | ILMN |
Illumina, Inc.
This page
|
5,605 | $985,527 | |
| 8 | VCYT |
Veracyte, Inc.
|
11,062 | $649,671 |
All Filings in ILMN
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $985,527 | 5,605 | Shares | Sole | 2026-08-04 | |
| 2025-12-31 | $863,032 | 6,580 | Shares | Sole | 2026-02-11 | |
| 2025-03-31 | $915,028 | 11,533 | Shares | Sole | 2025-05-13 | |
| 2024-09-30 | $464,650 | 3,563 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,594,508 | 15,276 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $371,313 | 2,704 | Shares | Sole | 2024-05-13 | |
| 2022-09-30 | $474,876 | 2,489 | Shares | Sole | 2022-11-07 | |
| 2022-03-31 | $473,087 | 1,354 | Shares | Sole | 2022-05-10 | |
| 2021-12-31 | $723,596 | 1,902 | Shares | Sole | 2022-02-09 | |
| 2021-09-30 | $346,796 | 855 | Shares | Sole | 2021-11-15 | |
| 2021-03-31 | $266,921 | 695 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||